The statement by Clark et al (March 1996; 51:325-6) that "the coefficient ofvariation for urinary salbutamol was approximately double that for plasma salbutamol" cannot be made with confidence until the authors have validated the protocol they are using. Hindle and Chrystyn' reported that the relative bioavailability of salbutamol to the lung could be used to compare two inhaled products/ inhalation methods by measuring the amount of salbutamol excreted in the urine in the first 30 minutes after inhalation. Since the method of Dr Chrystyn and colleagues has a detection limit of 50 ng/ml,3 this represents 50-fold lesser sensitivity than our assay (limit 1 ng/ml). Perhaps this explains why Dr Chrystyn continues to try to justify using the urinary method which is both indirect and more variable. This is evidenced by a recent study showing that it is possible to detect a 1-32-fold difference in lung bioavailability between CFC and non-CFC salbutamol formulations with plasma but not with urinary kinetic methods. 4 We therefore remain firmly of the opinion that direct measurement of plasma salbutamol kinetics is the only way to evaluate directly lung bioavailability in man.
The statement by Clark et al (March 1996; 51:325-6 ) that "the coefficient ofvariation for urinary salbutamol was approximately double that for plasma salbutamol" cannot be made with confidence until the authors have validated the protocol they are using. Hindle and Chrystyn' reported that the relative bioavailability of salbutamol to the lung could be used to compare two inhaled products/ inhalation methods by measuring the amount of salbutamol excreted in the urine in the first 30 minutes after inhalation. Their method was to start at time zero, inhale four consecutive doses (with one minute between each dose), and then provide a urine sample at time t =30 minutes. The protocol used by Clark et al is 12 sequential inhalations over six minutes and then a urine sample is collected for the measurement of salbutamol excretion 30 minutes after completion of the 12 inhalations. Thus, urine is collected over the first 36 minutes compared with 30 minutes for the method of Hindle and Chrystyn. This the authors confirmed during a poster discussion session at the British Thoracic Society's winter meeting in December 1995.
We have recently been involved with further studies to validate our method so that we can extend our work to the use of nebulisers. At present we have data on five healthy volunteers (three women) who swallowed 100 jig salbutamol solutions at t =0, 2, 4, 6, and 8 minutes and provided urine samples at 0, 30, 40, and 60 minutes after swallowing the first salbutamol dose. The mean (SD) rate of salbutamol urinary elimination from t = 0-30, 30-40, and 40-60 minutes was 0-08 (0-11), 0-72 (0 76), and 0 99 (0 38) jig/hour, respectively (data on file). Similar rates following the inhalation of five sequential 100 jig salbutamol inhalations at t =0, 2, 4, 6, and 8 minutes (that is, each separated by two minutes) were 25-80 (5 79), 24-16 (7-54) Since the method of Dr Chrystyn and colleagues has a detection limit of 50 ng/ml,3 this represents 50-fold lesser sensitivity than our assay (limit 1 ng/ml). Perhaps this explains why Dr Chrystyn continues to try to justify using the urinary method which is both indirect and more variable. This is evidenced by a recent study showing that it is possible to detect a 1-32-fold difference in lung bioavailability between CFC and non-CFC salbutamol formulations with plasma but not with urinary kinetic methods. 4 We therefore remain firmly of the opinion that direct measurement of plasma salbutamol This book represents a successful attempt to incorporate in a practical way the huge amount of information published regarding HIV and AIDS since the first edition in 1990. If anything, the term "pocket book" may understate the quantity of information which is concisely expressed on every aspect of HIV disease.
There are 18 chapters each by different authors with practical experience in their topic, although the editors have maintained throughout a uniformity of style of presentation which is thoroughly readable. Chapters on epidemiology and natural history and international aspects of HIV/AIDS outline the global spread of the disease and the important regional differences in natural history. Each chapter on the main organ systems initially provides a helpful differential diagnosis of common presenting symptoms (including some diagnoses not specific for HIV), then reviews the important conditions in more detail. These reviews are authoritative and well balanced between giving the practice of the author and providing an overview of current literature. The chapter on therapeutic guidelines comprehensively presents treatment regimes for the major opportunistic infections, including drug side effects and drug interactions. Chapters on HIV in pregnancy, paediatrics, and in relation to blood products and intravenous drug misuse provide updated information ofgreat use in counselling patients. Moreover, there is a chapter providing practical guidelines for counselling HIV patients in general. Especially useful and thoughtfully presented is the chapter on aspects of palliative and terminal care.
The book has an index and each chapter is referenced. There are a limited number of black and white illustrations.
This excellent book is particularly recommended to medical students, junior hospital doctors including MRCP students, and general practitioners in high prevalence areas. Chest physicians will find this book useful not only for information on the respiratory manifestations, but also on the diseases of other organ systems likely to coexist in their patients infected with HIV. - 
